PharmacyCodes



Flumazenilum [Latin] en es it fr

Flumazenilum [Latin] Brand names, Flumazenilum [Latin] Analogs

Flumazenilum [Latin] Brand Names Mixture

  • No information avaliable

Flumazenilum [Latin] Chemical_Formula

C32H26N4O2

Flumazenilum [Latin] RX_link

No information avaliable

Flumazenilum [Latin] fda sheet

Flumazenilum_[Latin] FDA

Flumazenilum [Latin] msds (material safety sheet)

Flumazenilum [Latin] Synthesis Reference

No information avaliable

Flumazenilum [Latin] Molecular Weight

498.575 g/mol

Flumazenilum [Latin] Melting Point

No information avaliable

Flumazenilum [Latin] H2O Solubility

Very slightly soluble (0.15 mg/mL at 23oC)

Flumazenilum [Latin] State

Solid

Flumazenilum [Latin] LogP

5.955

Flumazenilum [Latin] Dosage Forms

Liquid (ampule containing 20 mg conivaptan hydrochloride)

Flumazenilum [Latin] Indication

For the treatment of euvolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.

Flumazenilum [Latin] Pharmacology

Conivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.

Flumazenilum [Latin] Absorption

No information avaliable

Flumazenilum [Latin] side effects and Toxicity

Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.

Flumazenilum [Latin] Patient Information

No information avaliable

Flumazenilum [Latin] Organisms Affected

Humans and other mammals